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of needed raw data, r can be computed from relative risks, odds ratios, t statistics,
F statistics, chi square statistics, standard normal deviate Z statistics, and beta
coefficients. In studies reporting p-values only, p-values can be converted to their
associated one-tailed standard normal deviate Z values to allow the calculation of
r. Before computed r’s can be combined, theymust be transformed using the Fisher
Z transformation in order to normalize their distribution. The weighted and un-
weighted Fisher Z transformed r’s are then converted back to r’s, and the weighted
and unweighted mean r’s are calculated. Confidence intervals around these esti-
mates show the degree to which they significantly differ from zero. For the un-
weighted mean r, the random effects confidence interval is usually preferred. Al-
though such confidence interval tends to be wider, it allows generalization to
studies other than those included in the sample. This methodology is demon-
strated using a dataset from a systematic review of published scientific literature.
The analysis shows how diversely-reported effects sizes can be converted and
combined to produce a summary r, which explains the association between spe-
cific determinant and outcome variables. Despite the value of correlation r inmeta-
analysis, it continues to be underused in the synthesis of scientific evidence.
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Data requirements from reimbursement authorities globally vary greatly due to
variation in importance of HTA and levels of acceptable complexity in submitted
economic evidence. Oftenmarket differences have been addressed by global phar-
maceutical companies by developing value arguments that address the most de-
veloped reimbursement systems, which then have to be adapted locally, often
resulting in the duplication of effort among local affiliates. Placing customer re-
quirements and informal preferences as the starting point of the development of
value arguments can increase efficiency and more specifically meet local HTA
needs. Methodologies that will support development of locally adaptable value
arguments – both value dossiers as well as health economic messages - requires
first of all the understanding of local payer needs. Countries requiring submission
of economic data can be classified on the basis of commonly required assessment
methods – budget impact analysis, cost effectiveness analysis and cost minimisa-
tion analysis, as well as the complexity accepted in both submitted clinical and
economic evidence. This complexity is in terms of level of complexity of data
requirements for Health Economic analysis, technical modelling approach, CE out-
come, local/international data preference, preference for comparator, preferred
time horizon amongst others. This can be used to divide these countries into buck-
ets with similar requirements. Globally developed value arguments can be devel-
oped and adapted to these buckets of countries and their needs. Basing value
arguments that are developed globally as mentioned, and then sent to local affili-
ates to adapt to the specific needs of their HTA system, on the preferences of
customers is expected to be crucial to ensure local success for reimbursement.
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Unlike randomized controlled trials (RCTs), pragmatic clinical trials (PCTs) mea-
sure the relative benefits of competing treatments in actual practice, thus, are an
important pharmacoeconomic data source. Depending on the design features, tri-
als can vary in their degree of pragmatism. We undertook a brief review of the
literature to highlight specific PCT design considerations that optimize their utility
for health economic and outcomes research (HEOR) applications. A broad popula-
tion and active control groups, typical in PCTs, can help achieve generally repre-
sentative HEOR assessments and reduce reliance upon indirect comparisons. A
minimally restrictive protocol is needed to preserve a naturalistic focus, and for
reducing Hawthorne effects. Some control is required, however, tominimize study
biases. Randomization to initial treatment choice remains essential to avoid selec-
tion bias and confounding, but little control should be exerted on regimen changes
so that real-world prescribing patterns (switching, adding, and dropping) patterns
and patient behaviors (non-compliance, non-adherence) can be evaluated. In the
absence of blinding, ascertainment bias is also a risk; use of objectively measured
outcomes that may even be identifiable from medical charts can help. Capturing
clinical, resource utilization, safety, preference, and quality of life, outcomes can
lead to richer economic models, and better understanding of usual-care treatment
decisions. With a broad patient base, it is important to explore subgroup effects,
and to prioritize predictive analyses to identify response variation. Beyond a
thoughtful study design, key operational elements such as site selection, patient
recruitment and retention and ongoing study support are critical to PCT success.
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Themajority of new PROmeasures are developed in English, with a small minority
developed in other languages. This poses the question of how to translate and
linguistically validate measures developed in languages other than English, when
the resources are simply not available for translating from the source language (e.g.
Hungarian) into the target language (e.g. Bengali). The URAM Scale assesses func-
tional performance of the hand in patients with Dupuytren’s Contracture. It was
developed in French and initially translated and linguistically validated into UK
English. Themethodology employed for this translationwas the reverse of a typical
English to French translation, whereby the French in-country investigator acted as
the project manager and an in-house project manager (qualified in French to Eng-
lish translation) acted as the in-country investigator. The translation into English
required consultation with the developer and two issues needed to be resolved in
order to develop the UK English version. One item required alternative wording as
it mentioned wash mitts, which are very rarely used in the UK, and for another
item, two verbs were required to convey the meaning of a single French verb. On
completion of the translation, the UK English version was then used as a source
version for the translation of the URAM Scale into several other European lan-
guages. During this process the translators were asked to work from the English
version but to also consider the relevance of the original Frenchwording for the two
items that required a change in English. For example, in countries where wash
mitts are used, this wording was retained instead of the new English wording
which used ‘flannel’. This experience highlights the importance of always consid-
ering the original development language when translating a measure using a gen-
erated English version as the source.
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OBJECTIVES: To assess the rate of chemotherapy induced nausea and vomiting
(CINV) associatedwith palonosetron (a 5-hydroxy tryptamine3-receptor antagonist
[5-HT3-RA]) initiation versus other 5-HT3-RAs among patients with cancer on
highly [HEC] or moderately emetogenic chemotherapy (CT) [MEC] treatment in a
hospital outpatient setting.METHODS: Patients with a cancer diagnosis initiating
HEC or MEC and anti-emetic prophylaxis with palonosetron (Group 1) or other
5-HT3-RAs (Group 2) for the first time (index date) between 4/1/2007 – 3/31/2009
were identified from the Premier Perspective comparative database. Inclusion cri-
teria were patients aged 18 yearswith no evidence of nausea and vomiting or use
of HEC/MEC or anti-emetic medication in the 6-month pre-index date period, and
with 36-consecutive months of hospital data. Follow-up time was first of eight CT
cycles (a cycle was the unit of analysis) or six months post-index date. A negative
binomial distribution generalized linear multivariate regression model estimating
the CINV event rate on CT matched groups in the follow-up period was developed
after controlling for demographic and clinical variables. RESULTS: Of 6418 identi-
fied patients, 1522 (23.7%) initiated palonosetron. Group 1 patients comprised of
less African Americans (8.7% vs. 14.2%) and more Hispanics (5.7% vs. 4.5%);
p0.0001, more patients on HEC [50.5% vs. 41.5%; p0.0001], and more non-colon
gastrointestinal (10.3% vs. 6.3%) and breast cancer patients (19.5% vs. 16.8%);
p0.0001. In the follow-up period, the number of unadjusted CINV events between
the matched groups was lower for Group 1 [6957 vs. 7784; p0.054] patients. The
regressionmodel predicted a significant decrease (12.5%) in the CINV event rate per
CT cycle for Group 1 patients versus Group 2 patients; p0.0044. CONCLUSIONS: In
this retrospective hospital outpatient study, patientswith cancer treatedwithHEC/
MEC and initiated on palonosetron were more likely to experience a significantly
lower rate of CINV events versus those initiating other 5-HT3-RAs.
PCN2
SAFETY AND TREATMENT PATTERNS OF ANGIOGENESIS INHIBITORS IN
PATIENTSWITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE UNITED
KINGDOM: PRELIMINARY RESULTS OF AN ONGOING CHARTS REVIEW STUDY
Hawkins R1, Wagstaff J2, Nathan P3, Sarda SP4, Vekeman F5, Korves C4, Dasgupta S2,
O’Mara S1, Fitton S1, Hayers J1, Tham C1, Wei R4, Luka A4, Neary MP6, Duh MS4
1University of Manchester, Manchester, UK, 2Singleton Hospital, Swansea, UK, 3Mount Vernon
Cancer Center, Northwood, Middlesex, UK, 4Analysis Group, Inc., Boston, MA, USA, 5Analysis
Group, Inc., Washington, DC, USA, 6GlaxoSmithKline, Collegeville, PA, USA
OBJECTIVES: This study evaluated the rates of and reasons for treatment modifi-
cations and occurrence of adverse events (AEs) among patients treated with anti-
angiogenic agents in UK clinical practice. METHODS: Data from medical records
were retrospectively reviewed at 3 large UK oncology centers for mRCC patients
who were 18 years and received sunitinib (N90) as first-line treatment from
January 1, 2005 to October 15, 2010. Proportions of patients with treatment modi-
fications (i.e.: discontinuation, interruption, or dose change) and reasons for mod-
ifications were determined. Time to treatment discontinuation and proportion of
patients with all grade and grade 3/4 AEs were also determined. Data on clinician
assessed response rates was collected. RESULTS: Ten percent of patients were
cytokine-pretreated. Average daily dose over initial cycle was 31.98 mg; 77.8% of
patients started treatment with recommended dosing of 50 mg QD 4/2. Among the
62 patients with available tumor response assessments, 35.5% had an objective
response (OR; complete or partial response). A total of 84.4% of patients experi-
enced AEs; 24.4% experienced grade 3/4 AEs. The most commonly reported all
grade AEs were diarrhea (35.6%), mucositis/stomatitis (34.4%), and fatigue (26.7%);
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